Genetics Generation Advancement (ROCO:4160) Total Debt per Share: NT$4.52 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4160 Genetics Generation Advancement Corp ROCO:4160
72 GF Score
Price NT$39.15
GF Value NT$51.33
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Genetics Generation Advancement Total Debt per Share?

Genetics Generation Advancement ROCO:4160 +0.64% 72 Total Debt per Share is NT$4.52 as of Jun. 2026. GuruFocus rates ROCO:4160 with a GF Score™ of 72/100 and a GF Value™ of NT$51.33 (Modestly Undervalued). The stock has 8 warning signs investors should review.

NT$4.52 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Genetics Generation Advancement's Total Debt Per Share for the quarter that ended in Jun. 2026 was NT$4.52.

Genetics Generation Advancement Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Genetics Generation Advancement's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genetics Generation Advancement Total Debt per Share Chart

Genetics Generation Advancement Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.12 1.76 1.47 2.86

Genetics Generation Advancement Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 1.16 2.86 3.47 4.52
ROCO:4160
72GF Score
Genetics Generation Advancement Corp ROCO:4160
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genetics Generation Advancement Total Debt per Share Calculation

Genetics Generation Advancement's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(4.7+75.4)/28.0
=2.86

Genetics Generation Advancement's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(16.6+110.0)/28.0
=4.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of NT$4.52 mean?
Genetics Generation Advancement (ROCO:4160) has a Total Debt per Share of NT$4.52 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Genetics Generation Advancement and its competitors.
Is Genetics Generation Advancement's Total Debt per Share too high?
Genetics Generation Advancement's current Total Debt per Share is NT$4.52. Overall, Genetics Generation Advancement has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genetics Generation Advancement's Total Debt per Share compare to TMO and DHR?
Genetics Generation Advancement's Total Debt per Share of NT$4.52 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Medical Diagnostics & Research company?
A good Total Debt per Share depends on the Medical Diagnostics & Research industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Genetics Generation Advancement and its competitors. Genetics Generation Advancement's current Total Debt per Share is NT$4.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetics Generation Advancement stock overvalued right now?
Based on GuruFocus' analysis, Genetics Generation Advancement (ROCO:4160) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$51.33, compared to a current price of NT$39.15 — trading 23.7% below its estimated fair value. The current Total Debt per Share is NT$4.52. Genetics Generation Advancement's overall GF Score™ is 72/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Genetics Generation Advancement (ROCO:4160), the current Total Debt per Share is NT$4.52 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genetics Generation Advancement (ROCO:4160) Overvalued in 2026?

Based on GuruFocus' analysis, Genetics Generation Advancement stock appears to be undervalued. The current stock price of NT$39.15 is trading 23.7% below its estimated GF Value™ of NT$51.33. GuruFocus considers Genetics Generation Advancement to be Modestly Undervalued.

Key valuation signals for ROCO:4160:

  • Total Debt per Share: NT$4.52
  • GF Value™: NT$51.33 vs. price of NT$39.15 (23.7% below fair value)
  • GF Score™: 72/100 with 8 warning signs

No single metric tells the full story. See the ROCO:4160 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genetics Generation Advancement Business Description

Address No. 28, Lane 36, Xinhu 1st Road, 6th Floor, Neihu District, Taipei, TWN, 11494
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
72GF Score

Get the complete analysis for ROCO:4160

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$39.15
Price
NT$51.33
GF Value